RHOA and ischemia: This study investigated whether another RhoA/ROCK signaling pathway inhibitor, simvastatin, decreased MMP-2 activity in a rat model of ischemia-reperfusion injury by inhibiting the RhoA/ROCK pathway and reducing MMP-2 mRNA levels.